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Several clinical studies have shown that insulin resis-
tance is prevalent among patients with heart failure,
but the underlying mechanisms have not been fully
elucidated. Here, we report a mechanism of insulin
resistance associated with heart failure that involves
upregulation of p53 in adipose tissue. We found
that pressure overload markedly upregulated p53
expression in adipose tissue along with an increase
of adipose tissue inflammation. Chronic pressure
overload accelerated lipolysis in adipose tissue. In
the presence of pressure overload, inhibition of lipol-
ysis by sympathetic denervation significantly down-
regulated adipose p53 expression and inflammation,
thereby improving insulin resistance. Likewise, dis-
ruption of p53 activation in adipose tissue attenuated
inflammation and improved insulin resistance but
also ameliorated cardiac dysfunction induced by
chronic pressure overload. These results indicate
that chronic pressure overload upregulates adipose
tissue p53 by promoting lipolysis via the sympathetic
nervous system, leading to an inflammatory re-
sponse of adipose tissue and insulin resistance.
INTRODUCTION
The p53 tumor suppressor pathway coordinates DNA repair,
cell-cycle arrest, apoptosis, and senescence to preserve
genomic stability and prevent oncogenesis. Activation of p53 is
driven by a wide variety of stress signals that have the potential
to promote tumor formation, such as DNA damage, telomere
shortening, oxidative stress, and oncogene activation (Harris
and Levine, 2005; Meek, 2009; Vousden and Prives, 2009).
Recently, the contribution of p53 to many undesirable aspects
of aging and age-associated diseases, such as cardiovascular
and metabolic disorders, has been recognized (Royds and Iaco-
petta, 2006; Vousden and Lane, 2007). It has been reported thatCaging is associated with an increase of the p53-mediated tran-
scriptional activity (Edwards et al., 2007) and that slight constitu-
tive overactivation of p53 is associated with premature aging in
mice (Maier et al., 2004; Tyner et al., 2002). Activation of p53
has also been observed in aged vessels and failing hearts and
has been implicated in atherosclerosis and heart failure (Mina-
mino and Komuro, 2007, 2008; Sano et al., 2007). Recent find-
ings have indicated a role of p53 in determining the response
of cells to nutrient stress and in regulating metabolism (Vousden
and Ryan, 2009). It has also been demonstrated that excessive
calorie intake induces p53-induced inflammation in adipose
tissue, leading to insulin resistance and diabetes in mice (Mina-
mino et al., 2009).
A close link between heart failure and diabetes has long been
recognized in the clinical setting (Ashrafian et al., 2007; Lopa-
schuk et al., 2007; Witteles and Fowler, 2008). Many mecha-
nisms have been suggested to explain the increased incidence
of heart failure in diabetic patients, including the hypertrophic
influence of insulin, the adverse effects of hyperglycemia,
increased oxidative stress, and hyperactivity of neurohumoral
systems, such as the renin-angiotensin-aldosterone system
and the adrenergic system. Recently, increasing attention has
been paid to insulin resistance as a distinct cause of cardiac
dysfunction and heart failure in diabetic patients. A study of
Swedish patients without prior cardiac dysfunction found that
insulin resistance predicted the subsequent onset of heart failure
independently of established risk factors (Ingelsson et al., 2005).
In another clinical study, the plasma level of proinsulin (a marker
of insulin resistance) was found to be higher in patients who
subsequently developed heart failure than in control patients
20 years before the actual diagnosis of heart failure (Arnlo¨v
et al., 2001). These findings indicate that insulin resistance
precedes heart failure rather than being a consequence of it.
Evidence has emerged that myocardial insulin resistance is
central to altered metabolism in the failing heart and may play
a crucial role in the development of heart failure (Ashrafian
et al., 2007; Lopaschuk et al., 2007; Witteles and Fowler,
2008). The adaptive response of the failing heart involves
a complex series of enzymatic shifts and changes in the regula-
tion of transcriptional factors, which result in an increase of
glucose metabolism and a decrease of fatty acid metabolismell Metabolism 15, 51–64, January 4, 2012 ª2012 Elsevier Inc. 51
Cell Metabolism
Adipose Inflammation in Heart Failureto maximize the efficacy of energy production (Neubauer, 2007).
Insulin resistance of the myocardium inhibits these adaptive
responses, leading to increased reliance on fatty acid metabo-
lism. This increases oxygen consumption and decreases cardiac
function, raising the potential for lipotoxicity in the heart (Sharma
et al., 2007; Young et al., 2002). Another line of evidence indi-
cates that insulin signaling is upregulated in the failing heart
and that excessive cardiac insulin signaling exacerbates systolic
dysfunction (Shimizu et al., 2010).
Moreover, there is increasing evidence that heart failure recip-
rocally augments the risk of insulin resistance and clinical dia-
betes (Ashrafian et al., 2007). Insulin resistance and abnormal
glucose metabolism are very common in heart failure patients,
being identified in 43%of these patients, and such abnormalities
are associated with decreased cardiac function (Suskin et al.,
2000). Surprisingly, the link between heart failure and insulin
resistance grows stronger when patients with ischemic heart
disease are excluded (Witteles and Fowler, 2008). Heart failure
also predicts the development of type 2 diabetes in a graded
way (Tenenbaum et al., 2003). Although the above mentioned
clinical evidence supports a role of insulin resistance in the
occurrence of heart failure, evidence for the reciprocal statement
that heart failure promotes insulin resistance is largely associa-
tive. Moreover, the role of heart failure in the promotion of insulin
resistance has been demonstrated by only a few animal studies
(Nikolaidis et al., 2004; Shimizu et al., 2010) and the underlying
mechanisms are largely speculative.
Here, we studied the role of heart failure in the development of
insulin resistance and sought to elucidate the molecular mecha-
nisms involved. We found that insulin resistance developed in
two murine models of heart failure, a chronic pressure overload
model and a myocardial infarction model. Heart failure markedly
upregulated p53 expression in adipose tissue in association with
increased inflammation of adipose tissue. Heart failure acceler-
ated lipolysis in adipose tissue, whereas inhibition of lipolysis
by sympathetic denervation or treatment with a lipase inhibitor
significantly downregulated adipose tissue p53 expression and
inflammation, thereby improving insulin resistance. Likewise,
disruption of p53 activation in adipose tissue not only amelio-
rated inflammation in this tissue and improved insulin resistance
but also improved cardiac dysfunction associated with heart
failure.We conclude that heart failure upregulates p53 in adipose
tissue by promoting lipolysis via activation of the sympathetic
nervous system, leading to an inflammatory response of adipose
tissue and insulin resistance. Our results indicate that inhibition
of p53-induced adipose inflammation is a potential target for
treating metabolic abnormalities and systolic dysfunction in
patients with heart failure.
RESULTS
Pressure Overload Induces Adipose Tissue
Inflammation and Insulin Resistance
To examine the effect of cardiac pressure overload on glucose
homeostasis, we produced transverse aortic constriction (TAC)
in 11-week-old mice. In this mouse model, systolic cardiac
function deteriorated significantly along with left ventricular
(LV) dilatation 2–6 weeks after surgery (Figure S1A available on-
line). The insulin tolerance test (ITT) and the glucose tolerance52 Cell Metabolism 15, 51–64, January 4, 2012 ª2012 Elsevier Inc.test (GTT) showed that insulin sensitivity and glucose tolerance
were impaired at 4–6 weeks after TAC (Figure 1A) without any
change of food intake (Figure S1B). In patients with metabolic
disorders, the recruitment of inflammatory macrophages to
adipose tissue has been shown to increase the production of
proinflammatory cytokines, such as tumor necrosis factor
(TNF)-a and chemokine (C–C motif) ligand 2 (CCL2), also known
as monocyte chemoattractant protein-1 (MCP-1), leading to the
development of systemic insulin resistance (Hotamisligil et al.,
1993; Kamei et al., 2006; Weisberg et al., 2003). Therefore, we
investigated whether pressure overload provokes adipose tissue
inflammation. Examination of hematoxylin- and eosin-stained
sections demonstrated the infiltration of mononuclear cells
into visceral fat, with most of these cells being identified as
macrophages by immunofluorescent staining for Mac3 (Fig-
ure 1B). Consistent with these results, expression of a marker
for macrophages (Egf-like module containing, mucin-like, hor-
mone receptor-like 1; EMR1) and production of proinflammatory
cytokines were significantly upregulated in the adipose tissue of
TAC mice along with a decrease of adiponectin (Figure 1C)
compared with sham-operated mice. Treatment of TAC mice
with a neutralizing antibody for Tnf-a significantly improved
insulin resistance and glucose intolerance, suggesting a crucial
role in the upregulation of proinflammatory cytokines in the
development of metabolic abnormalities during heart failure
(Figure S1C).
Pressure Overload Increases Lipolysis and Induces
p53-Dependent Inflammation in Adipose Tissue
during Heart Failure
Computed tomography (CT) showed a significant decrease of
visceral fat after the creation of pressure overload (Figure 1D).
It is well accepted that sympathetic activity increases with heart
failure (Floras, 2009), and norepinephrine regulates lipolysis in
adipose tissue. We found that the norepinephrine levels of
plasma and adipose tissue increased significantly and plasma
fatty acid levels were markedly elevated in TAC mice compared
with sham-operated mice, suggesting acceleration of lipolysis
via the sympathetic nervous system in response to pressure
overload (Figure 1E). It has been reported that exposure to an
excess of fatty acids leads to p53 activation in various cells
(Zeng et al., 2008) and that p53 is crucially involved in the
regulation of adipose tissue inflammation in obese animals
(Minamino et al., 2009). Therefore, we hypothesized that chronic
pressure overload promotes lipolysis and the resultant increase
of fatty acids leads to p53-induced inflammation in adipose
tissue.
Consistent with this concept, we found that p53 expression
was upregulated in the adipose tissue of TACmice at 2–4 weeks
after surgery and the change was sustained until 6 weeks
(Figures 2A and S2A). To further investigate the role of adipose
tissue p53 in the response to pressure overload, we performed
TAC in adipocyte-specific p53 knockout (adipo-p53 KO) mice.
The pressure overload-induced increase of p53 expression
was attenuated in adipo-p53 KO mice compared with littermate
controls (Figure S2B). Production of proinflammatory cytokines
as well as cyclin-dependent kinase inhibitor 1A (Cdkn1a) expres-
sion was also decreased in adipo-p53 KO mice, along with
a decline in the infiltration of macrophages into visceral fat
Figure 1. Pressure Overload Induces Systemic Insulin Resistance and Adipose Tissue Lipolysis and Inflammation
(A) Insulin tolerance test (ITT) and glucose tolerance test (GTT) in mice at 6 weeks after sham operation (Sham) or TAC (n = 30).
(B) Hematoxylin and eosin staining of adipose tissues of mice at 6 weeks after sham operation (Sham) or TAC (upper panel). In the lower panel, the infiltration of
macrophages was evaluated by immunofluorescent staining for Mac3 (green). Nuclei were stained with Hoechst dye (blue). Scale bar, 50 mm. The right graph
indicates the quantitative data on the infiltration of macrophages (n = 5).
(C) Real-time PCR assessing the expression of Emr1, Tnf (Tnfa), Ccl2 (MCP1), and Adipoq (Adiponectin) levels in adipose tissues of mice at 6 weeks after sham
operation (Sham) or TAC (n = 10).
(D) CT analysis of mice at 6 weeks after sham operation (Sham) or TAC. The graph shows the ratio of visceral fat tissue weight estimated by CT to whole body
weight (n = 7).
(E) Norepinephrine level in adipose tissue (left) and plasma (middle), and plasma free fatty acid (FFA) level (right) of mice at 6 weeks after sham operation (Sham) or
TAC (n = 10). Data are shown as the means ± S.E.M. *p < 0.05, **p < 0.01.
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Adipose Inflammation in Heart Failure(Figures 2B and 2C). Consequently, adipo-p53 KOmice showed
improved insulin sensitivity and glucose tolerance after induction
of pressure overload compared with littermate controls (Fig-
ure 2D) without any change of food intake (Figure S2C). These
results suggest that p53 has a critical role in the regulation of
adipose tissue inflammation and insulin resistance during
pressure overload. In contrast, a decrease of fat mass and an
increase of plasma free fatty acids were observed to a similar
extent in both adipo-p53 KO and control mice after TAC (Figures
S2D–S2F), suggesting that pressure overload accelerates lipol-
ysis in a p53-independent manner.
Pressure Overload Promotes Lipolysis via the
Sympathetic Nervous System
We inhibited sympathetic activity in epididymal fat tissue by
surgical denervation and then performed TAC. As a result,
surgical denervation effectively inhibited an increase of the
norepinephrine level of adipose tissue and attenuated lipolysis
after the onset of pressure overload (Figures S3A and S3B and
data not shown). Histological examination of adipose tissue
showed that infiltration of inflammatory cells after TAC was
attenuated by denervation (Figures S3C and S3D). Likewise,
disruption of the sympathetic efferent nerves significantly
reduced pressure overload-induced upregulation of Emr1, a
proinflammatory cytokine expression in adipose tissue (Fig-
ure 3A), and this reduction was associated with significant
improvement of insulin resistance and glucose tolerance in
TAC mice (Figure 3B). Surgical denervation attenuated pressure
overload-induced upregulation of p53 and Cdkn1a expression
in adipose tissue (Figures 3A and 3C). We also pharmacologi-
cally inhibited the sympathetic activity in adipose tissue by
injecting guanethidine directly into epididymal fat and then
performed TAC. As a result, pharmacological denervation also
significantly inhibited lipolysis (Figures S3A and S3B) and atten-
uated upregulation of p53 and Cdkn1a expression and inflam-
mation in adipose tissues (Figures S3C, S3D, S4A and S4B).
Mice treated with guanethidine showed better insulin sensitivity
and glucose tolerance after creation of pressure overload (Fig-
ure S4C), indicating that pressure overload-induced activation
of the sympathetic nervous system accelerates lipolysis and,
thus, leads to adipose tissue inflammation and insulin resistance
in TAC mice.
Role of Lipolysis in the Regulation of Adipose p53
Expression and Inflammation
To examine the role of lipolysis in influencing adipose tissue
expression of p53 and inflammation after TAC, we inhibited lipol-
ysis by administering acipimox, a selective inhibitor of lipolysis,
to mice with TAC. Treatment with acipimox markedly inhibitedFigure 2. p53-Dependent Adipose Tissue Inflammation Provokes Syst
(A) Expression of p53 was examined in adipose tissues of mice by western blot a
used as an equal loading control. The graph indicates the quantitative data on p
(B) Real-time PCR assessing the expression of Emr1, Tnf (Tnfa),Ccl2 (MCP1), and
(adipo-p53 KO) and littermate controls (Cont) at 6 weeks after sham operation o
(C) Hematoxylin and eosin staining of adipose tissues of adipocyte-specific p53
sham operation (Sham) or TAC procedure. Scale bar, 50 mm. The right graph ind
(D) Insulin tolerance test (ITT) and glucose tolerance test (GTT) in adipocyte-speci
operation (Sham) or TAC procedure (n = 16). Data are shown as the means ± S.E
Clipolysis and also reduced infiltration of inflammatory cells into
adipose tissueduring pressure overload (FiguresS3A–S3D). Inhi-
bition of lipolysis also significantly reduced pressure overload-
induced upregulation of Emr1 and proinflammatory cytokine
production in adipose tissue (Figure 4A), along with significant
improvement of insulin resistance and glucose intolerance in
TAC mice (Figure 4B). Furthermore, treatment with acipimox
attenuated pressure overload-induced upregulation of p53 and
Cdkn1a expression in adipose tissue (Figures 4A and 4C), con-
firmingaclose relationshipbetween lipolysis andp53expression.
Next, we promoted lipolysis by administering isoproterenol
to mice via an infusion pump. Treatment with isoproterenol
significantly decreased the visceral fat mass and increased
plasma fatty acid levels (Figures S5A–S5C) and increased p53
expression in adipose tissue (Figure 5A). Isoproterenol also
induced adipose tissue inflammation (Figures 5B and 5C). To
further investigate the role of lipolysis in the regulation of p53
expression and inflammation in adipose tissue, we tested the
influence of deleting adipose triglyceride lipase (patatin-like
phospholipase domain containing protein 2, encoded by Pnpla2;
hereafter referred to as Atgl) on adipose tissue expression of
p53. It has been reported that Atgl homozygous KO mice show
massive accumulation of lipids in the heart, causing cardiac
dysfunction and premature death (Haemmerle et al., 2006).
When we generated TAC mice, we also noted that cardiac func-
tion was worse and LV enlargement was more marked in Atgl
heterozygous KO mice compared with their littermates (Fig-
ure S5D). In fact, most of the KO mice died of heart failure within
4 weeks after TAC. Therefore, we utilized Atgl-deficient adipose
tissue for ex vivo experiments. We cultured epididymal fat pad
tissues from Atgl KOmice or wild-type littermates and examined
the effect of isoproterenol on p53 expression. Treatment of wild-
type fat pads with isoproterenol significantly induced lipolysis
(Figure 5D) and upregulated the expression of both p53 and
Cdkn1a expression (Figures 5E and 5F). Disruption of Atgl in-
hibited isoproterenol-induced lipolysis (Figure 5D) and pre-
vented the upregulation of adipose p53 and Cdkn1a expression
(Figures 5E and 5F), suggesting a crucial role of lipolysis in the
regulation of p53 expression and inflammation in adipose tissue.
Myocardial Infarction Induces Adipose Tissue
Inflammation and Insulin Resistance
To investigate whether myocardial infarction (MI) induced insulin
resistance, we created MI in 11-week-old mice and assessed
the animals 6 weeks after surgery. Insulin sensitivity and
glucose tolerance were significantly impaired in MI mice com-
pared with sham-operated mice (Figure S5E). Significant loss
of fat tissue was also observed in MI mice (Figures S5F and
S5G) and this was associated with upregulation of adiposeemic Insulin Resistance during Heart Failure
nalysis at indicated time points after sham operation (Sham) or TAC. Actin was
53 expression (n = 3).
Cdkn1a (p21) levels in adipose tissue of adipocyte-specific p53-deficient mice
r TAC procedure (n = 12).
-deficient mice (adipo-p53 KO) and littermate controls (Cont) at 6 weeks after
icates the quantitative data on the infiltration of macrophages (n = 4).
fic p53-deficient mice (KO) and littermate controls (Cont) at 6 weeks after sham
.M. *p < 0.05, **p < 0.01.
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Figure 3. Surgical Transection of the Sympathetic Nerves Attenuates Adipose Tissue Inflammation and Systemic Insulin Resistance
(A) Real-time PCR assessing the expression of Emr1, Tnf (Tnfa),Ccl2 (MCP1), andCdkn1a (p21) levels in adipose tissues of mice at 6 weeks after sham operation
(Sham) or TAC with or without surgical transection of the sympathetic nerves (Denervation) of epidydimal fat (n = 8).
(B) Insulin tolerance test (ITT) and glucose tolerance test (GTT) ofmice at 6 weeks after shamoperation (Sham) or TACwith or without surgical denervation (n = 20).
(C) Western blot analysis of p53 in adipose tissues of mice at 6 weeks after sham operation (Sham) or TAC with or without surgical denervation. The right graph
indicates the quantitative data on p53 expression (n = 3). Data are shown as the means ± S.E.M. *p < 0.05, **p < 0.01.
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Inhibition of p53 activation in adipose tissue by genetic dis-
ruption significantly attenuated inflammation of this tissue and
improved metabolic abnormalities (Figures S5K and S5L). These
results suggest that the same mechanism underlies insulin
resistance associated with heart failure due to both pressure
overload and MI.56 Cell Metabolism 15, 51–64, January 4, 2012 ª2012 Elsevier Inc.Influence of Inhibiting p53-Induced Adipose Tissue
Inflammation on Cardiac Function
To investigate whether inhibition of p53-induced adipose tissue
inflammation could influence cardiac function in the develop-
ment of heart failure, we performed TAC and monitored cardiac
function in adipo-p53 KO mice. We found that adipo-p53 KO
mice showed significantly better cardiac function and less LV
Figure 4. Treatment with a Lipolysis Inhibitor Ameliorates Adipose Tissue Inflammation and Systemic Insulin Resistance
(A) Real-time PCR assessing the expression of Emr1, Tnf (Tnfa), Ccl2 (MCP1), and Cdkn1a (p21) levels in adipose tissue of mice at 6 weeks after sham operation
(Sham) or TAC with or without acipimox treatment (n = 8).
(B) Insulin tolerance test (ITT) and glucose tolerance test (GTT) of mice at 6 weeks after sham operation (Sham) or TACwith or without acipimox treatment (n = 32).
(C) Western blot analysis of p53 in adipose tissues of mice at 6 weeks after sham operation (Sham) or TAC with or without acipimox treatment. Actin was used as
an equal loading control. The right graph indicates the quantitative data on p53 expression (n = 3). Data are shown as the means ± S.E.M. *p < 0.05, **p < 0.01.
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They also showed better survival during the chronic phase of
heart failure (Figure 6B). Similar results were observed in another
model of heart failure induced by MI (Figure S6A). Furthermore,
administration of a p53 inhibitor (pifithrin-a) into the adipose
tissue of the TAC or MI model mice after the onset of heart failure
improved cardiac dysfunction, as well as adipose tissue inflam-
mation, and metabolic abnormalities (Figures 6C–6E and S6B–
S6D), indicating that inhibition of p53 may be useful for the
treatment of heart failure and its associated metabolic abnor-
malities. Moreover, we noted significant improvement of cardiac
function after sympathetic nerve blockade (Figures S6E and
S6F). However, treatment of TAC mice with acipimox was foundCto exacerbate cardiac dysfunction (Figure S6G), presumably
because it impaired fatty acid metabolism and energy produc-
tion in cardiomyocytes, as reported previously (Tuunanen
et al., 2006).
Mechanism of p53-Induced Adipose Tissue
Inflammation during Heart Failure
Because our results indicated that adrenergic activation induced
lipolysis that upregulated p53 and promoted adipose tissue
inflammation, we speculated that an excess of fatty acids might
be involved in the upregulation of p53 in adipose tissue. There-
fore, we examined the effect of palmitic acid on cultured preadi-
pocytes. Treatment with palmitic acid significantly increased theell Metabolism 15, 51–64, January 4, 2012 ª2012 Elsevier Inc. 57
Figure 5. Role of Lipolysis in the Regulation of Adipose p53 Expression and Inflammation
(A) Western blot analysis of p53 in adipose tissues of wild-typemice treated with PBS or isoproterenol (ISO). Actin was used as an equal loading control. The right
graph indicates the quantitative data on p53 expression (n = 3).
(B) Real-time PCR assessing the expression of Emr1, Tnf (Tnfa), and Ccl2 (MCP1) levels in adipose tissues of wild-type mice treated with PBS or isoproterenol
(ISO) (n = 8).
(C) Hematoxylin and eosin staining of adipose tissues of wild-type mice treated with PBS or isoproterenol (ISO). Scale bar, 50 mm. The right graph indicates the
quantitative data on macrophage infiltration (n = 4).
(D) The changes in weight of adipose tissues isolated from Atgl-deficient mice (KO) and littermate controls (Cont) after treatment with PBS or isoproterenol (ISO)
(n = 6).
(E) Expression of p53 was examined in adipose tissues of Atgl-deficient mice (KO) and littermate controls (Cont) treated with PBS or isoproterenol (ISO) by
western blot analysis. The right graph indicates the quantitative data on p53 expression (n = 3).
(F) Real-time PCR assessing the expression of Cdkn1a (p21) level in adipose tissues isolated from Atgl-deficient mice (KO) and littermate controls (Cont) after
treatment with PBS or isoproterenol (ISO) (n = 6). Data are shown as the means ± S.E.M. *p < 0.05, **p < 0.01.
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DNA damage, as demonstrated by the increase of gH2AX, which
in turn upregulated p53 expression (Figures 7A–7C, S7A, and
S7B). This upregulation of p53 was associated with an increase
of NF-kB activity and proinflammatory cytokine expression
(Figures 7D and 7E). Because it has been reported that p5358 Cell Metabolism 15, 51–64, January 4, 2012 ª2012 Elsevier Inc.enhances the activity of NF-kB, which regulates various cyto-
kines including TNF-a and CCL2 (Benoit et al., 2006; Ryan
et al., 2000), we examined the relationship between p53 ex-
pression and NF-kB activation. We demonstrated that the
disruption of p53 expression significantly attenuated palmitic
acid-induced activation of NF-kB and upregulation of Ccl2
Figure 6. Influence of Inhibiting p53-Induced Adipose Tissue Inflammation on Cardiac Function
(A) Echocardiography to assess systolic function (FS) and ventricular size (LVDs) in adipocyte-specific p53-deficient mice (adipo-p53 KO) and littermate controls
(Cont) at 6 weeks after sham operation or TAC (n = 8). FS, fractional shortening; LVDs, left ventricular end-systolic diameter.
(B) Survival rate of adipocyte-specific p53-deficient mice (adipo-p53 KO) and littermate controls (Cont) after TAC procedure (n = 25).
(C) Pifithrin-a (PFT) was administered into the adipose tissue of mice at 2–4 weeks after TAC, and systolic function (FS) and ventricular size (LVDs) were estimated
before (2w, 2 weeks after TAC) and after (4w, 4 weeks after TAC) treatment by echocardiography (n = 5).
(D) Real-time PCR assessing the expression of Emr1, Tnf (Tnfa), and Ccl2 (MCP1) levels in adipose tissue of mice at 4 weeks after sham operation or TAC with or
without pifithrin-a (PFT) treatment (n = 4).
(E) Insulin tolerance test (ITT) and glucose tolerance test (GTT) of mice at 4 weeks after sham operation or TAC with or without pifithrin-a (PFT) treatment (n = 12).
Data are shown as the means ± S.E.M. *p < 0.05, **p < 0.01.
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Adipose Inflammation in Heart Failure(Figures 7D and 7E), whereas knockdown of the NF-kB compo-
nent p50 markedly inhibited palmitic acid-induced upregulation
of Ccl2 (Figure 7E). In addition, treatment with an antioxidant in-
hibited palmitic acid-induced DNA damage and upregulation of
p53 (Figures S7A and S7B). We also found that ROS andCgH2AX expression were increased in the adipose tissue of
mice with heart failure (Figures 7F and 7G). Furthermore, nuclear
localization of p50 was enhanced in adipose tissue during heart
failure (Figures 7H and S7C). This increase of nuclear p50
expression and the upregulation of proinflammatory cytokinesell Metabolism 15, 51–64, January 4, 2012 ª2012 Elsevier Inc. 59
Figure 7. Mechanism of p53-Induced Adipose Tissue Inflammation during Heart Failure
(A) Dihydroethidium (DHE) staining (red) of preadipocytes treated with vehicle (Cont) or palmitic acid (500 mM) for 10 min. Nuclei were stained with Hoechst dye
(blue). Scale bar indicates 50 mm. The right graph indicates the quantitative data on DHE-positive area (n = 4).
(B) Immunofluorescent staining for g-H2AX (red) in preadipocytes treated with vehicle (Cont) or palmitic acid (500 mM) for 1 hr. Nuclei and plasma membranes
were stained with Hoechst dye (blue) and Wheat Germ agglutinin lectin (green). Scale bar indicates 50 mm.
(C) Western blot analysis of phospho-p53 and p53 expression in preadipocytes treated with vehicle (Cont) or palmitic acid (500 mM).
(D) Small-interfering RNA targeting p53 (sip53) or negative control RNA (siNC) was introduced into preadipocytes treated with or without palmitic acid (500 mM) for
12 hr. The NF-kB activity was examined by luciferase assay (n = 5).
(E) Real-time PCR assessing the expression ofCdkn1a (p21) andCcl2 (MCP1) levels in preadipocytes prepared in Figure 7D (n = 9). The effect of small-interfering
RNA targeting the NF-kB component p50 (sip50) on the expression of Ccl2 (MCP1) was also examined (n = 9).
(F) Dihydroethidium (DHE) staining (red) in adipose tissue from sham-operated (Sham) and TAC mice. Nuclei were stained with Hoechst dye (blue). Scale bar
indicates 20 mm. The right graph indicates the quantitative data on DHE-positive area (n = 5).
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7H, and S7C). Moreover, treatment with a lipolysis inhibitor
significantly inhibited the heart failure-induced increase of ROS
and nuclear p50 expression (Figures S7D and S7E). Inhibition
of NF-kB activation in adipose tissue by BAY 11-7082 also signif-
icantly attenuated adipose tissue inflammation and improved
metabolic abnormalities and cardiac dysfunction in TAC mice
(Figures S7F–S7H). These results indicate that adrenergic acti-
vation by heart failure induces lipolysis in adipose tissue, which
increases DNA damage due to ROS and thus upregulates p53.
Activation of p53 then induces adipose tissue inflammation
and metabolic abnormalities by upregulating the expression of
NF-kB-dependent proinflammatory cytokines.
DISCUSSION
Although treatments that achieve neurohumoral antagonism
have successfully reduced the morbidity and mortality of heart
failure, the death rate remains unacceptably high (Kannel,
2000). Variousmetabolic abnormalities are associated with heart
failure, and recent data have suggested that heart failure itself
promotes adverse changes of metabolism, such as systemic
insulin resistance (Ashrafian et al., 2007; Witteles and Fowler,
2008). Thus, a detrimental vicious cycle may be postulated, in
which heart failure induces insulin resistance that in turn acceler-
ates cardiac dysfunction (Opie, 2004). However, studies on the
molecular mechanisms of such metabolic abnormalities in heart
failure are largely preliminary and the results have sometimes
been conflicting. In the present study, we demonstrated a causal
role for heart failure in the development of insulin resistance by
using two mouse models of heart failure, and we elucidated
the underlying mechanisms. We found that the hyperadrenergic
state of heart failure initiated a vicious metabolic cycle by
promoting lipolysis in adipose tissue that increased the release
of free fatty acids and upregulated p53 expression and proin-
flammatory cytokine production in adipose tissue, which then
promoted systemic insulin resistance. Cardiac insulin resistance
is considered to contribute to the development of heart failure.
Because excessive cardiac insulin signaling has been reported
to exacerbate systolic dysfunction in both TAC and MI models
(Shimizu et al., 2010), hyperinsulinemia associated with systemic
insulin resistance may also have a pathological role in heart
failure until insulin resistance becomes evident in the myocar-
dium. Inhibition of lipolysis by sympathetic denervation or by
treatment with a lipolysis inhibitor improved insulin resistance
in our heart failure model. Plasma free fatty acid levels were
significantly elevated after the onset of heart failure, whereas
this increase was attenuated by inhibition of lipolysis with acipi-
mox, denervation, or guanethidine. Disruption of p53 in adipose
tissue also markedly attenuated adipose inflammation and
metabolic abnormalities associated with heart failure, whereas
fatty acid levels were unaffected. Thus, adipose tissue inflamma-(G) The number of g-H2AX-positive nuclei (white arrows and inset) in adipose ti
estimated by immunofluorescent staining for g-H2AX (red) (n = 5). Nuclei and
agglutinin lectin (green). Scale bar indicates 50 mm.
(H) The number of p50-positive nuclei in adipose tissue of adipocyte-specific p
after sham operation (Sham) or TAC procedure was estimated by immunofluores
**p < 0.01.
Ction rather than the increase of plasma free fatty acids per se is
involved in the impairment of insulin sensitivity and glucose toler-
ance associated with heart failure. We also noted that p53 was
modestly upregulated in the liver and skeletal muscle, presum-
ably due to the increase of circulating free fatty acids. However,
we did not detect a strong inflammatory response in those
tissues under our experimental conditions (I. Shimizu and
T. Minamino, unpublished data), suggesting that upregulation
of adipose tissue p53 is more important for the development
of metabolic abnormalities during heart failure. This concept is
further supported by our finding that disruption of p53 activation
in adipose tissue nearly normalized insulin resistance and
glucose intolerance provoked by heart failure.
We observed that systolic cardiac function and survival with
chronic heart failure were significantly better for adipo-p53 KO
mice than their control littermates. Suppression of p53 activity
in adipose tissue by administration of a p53 inhibitor after the
onset of heart failure improved cardiac dysfunction and also
reduced adipose tissue inflammation and metabolic abnormali-
ties in both the TAC and MI models. Inhibition of NF-kB activity
in adipose tissue also improved cardiac dysfunction, as well as
adipose tissue inflammation and insulin resistance. Improve-
ment of cardiac dysfunction by disruption of p53 in adipose
tissue was not associated with a decrease of plasma free fatty
acid levels. Systemic inhibition of lipolysis (Atgl deficiency or aci-
pimox treatment) and disturbance of lipolysis in adipose tissue
(denervation or guanethidine treatment) significantly reduced
plasma free fatty acid levels (Haemmerle et al., 2006). However,
the former intervention accelerated heart failure, whereas
cardiac dysfunction was improved by the latter. Thus, the bene-
ficial effect of inhibiting p53-induced adipose tissue inflamma-
tion on cardiac function is independent of changes in circulating
free fatty acid levels, and lipolysis in cardiomyocytes appears to
have a crucial role in cardiac metabolism and energy production.
Although there is evidence suggesting that p53 has a protective
role against damage due to ROS and lipotoxicity (Bazuine et al.,
2009), our results indicate that chronic activation of p53 in
adipose tissue causes inflammation and that inhibition of p53-
induced adipose tissue inflammation is a potential target for
treating metabolic abnormalities and systolic dysfunction in
patients with heart failure.
Adipose tissue was traditionally considered to be a simple
energy storage organ, but it is now appreciated that it also has
endocrine functions and secretes a variety of factors referred
to as adipokines (Donath and Shoelson, 2011; Hotamisligil,
2006; Ouchi et al., 2011). With high calorie intake, the size and
number of adipocytes increase, and hypertrophic adipocytes
shift the balance toward production of proinflammatory adipo-
kines. This shift in the adipokine profile causes the modification
of adipose tissue macrophages from the anti-inflammatory M2
type to the proinflammatory M1 type, and further increases
the production of proinflammatory molecules, which in turnssue of mice at 6 weeks after sham operation (Sham) or TAC procedure was
plasma membranes were stained with Hoechst dye (blue) and Wheat Germ
53-deficient mice (adipo-p53 KO) and littermate controls (Cont) at 6 weeks
cent staining for p50 (n = 6). Data are shown as the means ± S.E.M. *p < 0.05,
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flamed fatty tissue. Adipokines produced by inflamed adipose
tissue have been suggested to play a crucial role in the regulation
of glucose and lipid metabolism and to contribute to the devel-
opment of diabetes (Donath and Shoelson, 2011; Hotamisligil,
2006; Ouchi et al., 2011). It has been reported that excessive
calorie intake leads to accumulation of ROS in adipose tissue
and subsequently causes DNA damage that activates p53 (Min-
amino et al., 2009). In contrast to obesity, heart failure decreases
body fat tissue mass by inducing lipolysis. Accelerated lipolysis
and a subsequent increase of free fatty acids are likely to cause
p53 activation because we found that the promotion of lipolysis
by treatment with isoproterenol upregulated adipose tissue
expression of p53, whereas inhibition of lipolysis by acipimox
or disruption of lipase activity attenuated p53 expression. These
results are consistent with a recent report describing that fast-
ing-induced lipolysis promotes an immune response in murine
adipose tissue (Kosteli et al., 2010). Various molecular mecha-
nisms of p53 activation by heart failure may be postulated,
including hypoxia, increased oxidative stress, and induction of
endoplasmic reticulum stress (Harris and Levine, 2005; Schenk
et al., 2008). Our in vitro and in vivo studies have indicated that
an increase of free fatty acids causes ROS-induced DNA
damage that upregulates p53 in adipose tissue. Activation of
p53 then upregulates the expression of proinflammatory adipo-
kines via the NF-kB signaling pathway and promotes systemic
insulin resistance.
The b-blockers are competitive antagonists of b-adrenergic
receptors. At one time, b-blockers were contraindicated in
patients with heart failure due to their negative inotropic effect.
However, several large-scale clinical trials demonstrated the
efficacy of b-blockers for reducing morbidity and mortality in
heart failure patients with impaired systolic function, so
b-blockers are now recommended as first-line agent for these
patients (Hjalmarson et al., 2000; Leizorovicz et al., 2002; Packer
et al., 2001, 2002). A reduction of heart rate due to inhibition of
cardiac b1-adrenergic receptors is believed to be responsible
for most of the therapeutic benefits associated with b-blocker
treatment, although this is not the only mechanism of action
that may be important in heart failure. It is interesting that treat-
ment with a nonselective b-blocker (carvedilol) achieved a more
marked improvement of survival in patients with chronic heart
failure than treatment with a b1-selective blocker (metoprolol)
(Poole-Wilson et al., 2003), whereas new-onset diabetes was
frequent in heart failure patients during treatment with the
b1-selective blocker (Torp-Pedersen et al., 2007). It has been
reported that carvedilol antagonizes the b3-adrenergic receptor
as well as the b1/2-adrenergic receptors (Schnabel et al., 2000).
Taking our results together with these reports, it seems that
inhibition of b3-adrenergic activity in adipose tissue partially
accounts for the better clinical outcome in patients treated with
this nonselective b-blocker. Recent evidence has suggested
that treatment with insulin sensitizers improves systolic function
of the failing heart in animal models (Asakawa et al., 2002; Nem-
oto et al., 2005) but such treatment increases the incidence of
heart failure in diabetic patients, presumably because of sodium
retention (Home et al., 2009). Inhibition of p53-induced adipose
tissue inflammation could be an alternative therapeutic target to
block the metabolic vicious cycle in patients with heart failure.62 Cell Metabolism 15, 51–64, January 4, 2012 ª2012 Elsevier Inc.EXPERIMENTAL PROCEDURES
Animal Models
All animal study protocols were approved by the Chiba University review
board. C57BL/6 mice were purchased from the SLC Japan (Shizuoka, Japan).
TAC and MI were performed in 11-week-old male mice as described previ-
ously (Harada et al., 2005; Sano et al., 2007). Sham-operated mice underwent
the same procedure except for aortic constriction. Mice that expressed Cre
recombinase in adipocytes (Fabp4-Cre) were purchased from Jackson Labo-
ratories. We then crossed Fabp4-Cre mice (with a C57BL/6 background) with
mice that carried floxed Trp53 alleles with a C57BL/6 background (Marino
et al., 2000) to generate adipocyte-specific p53 knockout mice. The genotype
of littermate controls was Fabp4-Cre- Trp53 flox/flox. The generation and geno-
typing of Atgl-deficient mice has been described previously (Haemmerle et al.,
2006). Surgical or chemical denervation was performed before TAC operation
as described previously (Demas and Bartness, 2001; Foster and Bartness,
2006), with slight modification. In brief, the epidydimal fat pad was gently
separated from the skin and the abdominal wall by using a dissecting micro-
scope. For surgical denervation, a drop of 1% toluidine blue was applied to
the fat pad to facilitate visualization of the nerves. The nerves were then freed
from the surrounding tissue and vasculature and cut in two or more locations,
and the segments were removed to prevent possible reconnection. Chemical
denervation was performed by the local injection of guanethidine sulfate
(400 mg, Santa Cruz) into bilateral epidydimal fat. Sham-operated mice for
surgical denervation underwent the same procedure except for transection
of the nerve. For the control group for chemical denervation, saline was in-
jected into adipose tissue rather than guanethidine. Acipimox (Sigma) were
provided in drinking water (at a concentration of 0.05%) for 6 weeks after
TAC operation as described previously (Guo et al., 2009). Isoproterenol
(30 mg/kg/day, Sigma) were delivered by infusion pump (DURECT Corpora-
tion) for 2 weeks as described previously (Iaccarino et al., 1999). The local
injection of pifithrin-a (2.2 mg/kg/week, Carbiochem) or BAY 11-7082
(20 mg/kg/week, Carbiochem) into bilateral epidydimal fat was performed to
inhibit adipose p53 or NF-kB activity, respectively, from 2 weeks to 4 weeks
after operation.
Physiological and Histological Analyses
Echocardiography was performed with a Vevo 770 High Resolution Imaging
System (Visual Sonics Inc, Toronto, Ontario, Canada). To minimize variation
of the data, the heart rate was always approximately 550–650 beats perminute
when cardiac function was assessed. Epidydimal fat samples were harvested
and fixed in 10% formalin overnight. The samples were embedded in paraffin
and sectioned (Narabyouri research Co., Ltd). The sections were subjected to
immunohistochemistry or HE staining. The antibodies used are Mac3-specific
primary antibody (PharMingen) for macrophages, p50-specific primary anti-
body (Cell signaling), and phospho-H2AX-specific antibody (Cell signaling).
Laboratory Tests
For the intraperitoneal glucose tolerance test (IGTT), mice were starved for
6 hr and were given glucose intraperitoneally at a dose of 2 g / kg (body weight)
in the early afternoon. For the insulin tolerance test, mice were given human
insulin intraperitoneally (1 U / kg body weight) at 1:00 pm without starvation.
Blood glucose levels were measured with a glucose analyzer (Roche Diagnos-
tics). We analyzed free fatty acid (Biovision, Inc) and norepinephrine levels
(LDN) by using ELISA-based immunoassay kits according to the manufac-
turer’s instruction.
Western Blot Analysis
The lysates were resolved by SDS-polyacrylamide gel electrophoresis.
Proteins were transferred to a polyvinylidene difluoride membrane (Millipore,
Bedford, MA), which was incubated with the primary antibody followed by
anti-rabbit or anti-mouse immunoglobulin-G conjugated with horseradish
peroxidase (Jackson, West Grove, PA).
Cell Culture
Human preadipocytes were purchased from Sanko (Tokyo, Japan) and were
cultured according to the manufacturer’s instructions. NIH 3T3-L1 cells were
cultured in high-glucose DMEM plus 10% fetal bovine serum.
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Epididymal fat was extracted fromAtgl-deficient or littermatemice at 17weeks
of age. Freshly isolated fat pads (100–120 mg) were incubated in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum in the
presence of isoproterenol (10 mM) for 48 hr. Fat pads were treated with PBS
instead of isoproterenol in the control group.
Statistical Analysis
Data are shown as the mean ± SEM. Differences between groups were
examined by Student’s t-test or ANOVA followed by Bonferroni’s correction
for comparison of means. For survival analysis, the Kaplan-Meier method
and log-rank test were used. For all analyses, p < 0.05 was considered statis-
tically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at doi:10.1016/
j.cmet.2011.12.006.
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